In the future it will be common practice to use stem cell products to treat illnesses in the same way we use medications today
Pipeline
- ADSC for the treatment of Multiple Sclerosis (MS)
- Clinical trial: A Prospective, Single Center, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety and Efficacy of an Intrathecal Administration of SCM-010 in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
- SCM-010_Poster for 7th International Israeli stem cell conferance November 2019 final
- Anti-BMP small molecules for the treatment of MS
- Genetically modified muscle progenitor cells (MPCs) that secrete neurotropic factors (NTFs)
- MPC-NTFs: peripheral nerve injury
- MPC-NTFs: neuropathic pain
- Stem Cell Medicine – ISCT 2018 Poster
- Mesenchymal stem cell derived vesicles – exosomes secreted from cells for the treatment of autistic disorders
- Adipose-derived stem cell (ADSC) secreted factors: cosmetic products
- Production and Supply of Finolim (Fingolimod, Gilenia™)